BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 10
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27

• Business

  Juvenile Diabetes Research FoundationTeams Up With Pfizer Inc.'s Centers for Therapeutic Innovation to Support Novel Translational Research in Type 1 Diabetes

  November 4, 2013

   · 

  2 min read
• Drug Development

  Auris Medical AG Reaches Special Protocol Assessment Agreement With FDA for Pivotal Phase III Clinical Trial With AM-101 in Treatment of Acute Peripheral Tinnitus

  November 4, 2013

   · 

  3 min read
• Business

  NeoStem, Inc. Subsidiary Progenitor Cell Therapy Announces Cell Therapy Manufacturing Collaboration With ATMI

  November 4, 2013

   · 

  1 min read
• Drug Development

  Sangamo BioSciences, Inc. Presents Clinical Data From SB-728-T HIV Study Demonstrating Long-Term Immune Reconstitution and Reduction in the HIV DNA Reservoir in Subjects With Long-Term Infection

  November 4, 2013

   · 

  7 min read
• Business

  Jeffrey A. Duchemin Appointed to Additional Roles of President and Director of Harvard Bioscience Inc.

  November 4, 2013

   · 

  1 min read
• Business

  Thomson Reuters and NuMedii Launch Ground-Breaking Initiative to Identify Drugs for Repurposing

  November 4, 2013

   · 

  4 min read
• Policy

  Trial Date Set for Napo Pharmaceuticals, Inc. Breach of Contract Claim Against Salix Pharmaceuticals, Ltd.

  November 4, 2013

   · 

  3 min read
• Nordion International Shares How the Science of Irradiation is Solving Today’s Unique Global Product Challenges

  November 4, 2013

   · 

  1 min read
• Drug Development

  Alfact Innovation Announces Positive Clinical Trial Results for Treatment of AIH- and HBV- Related Acute-on-Chronic Liver Diseases

  November 4, 2013

   · 

  1 min read
• Drug Development

  Merck & Co., Inc.’s Investigational 9-valent HPV Vaccine, V503, Prevented 97 Percent of Cervical, Vaginal and Vulvar Pre-Cancers Caused by Five Additional HPV Types, in Phase 3 Study

  November 4, 2013

   · 

  1 min read